Analyst Coverage

The following research analysts cover Destiny Pharma.

Mark Brewer, finnCap	+44(0)20 7220 0500
Andy Smith, Equity Development	+44(0)20 7065 2690

Please click on links below to access coverage published:

	finnCap Analyst research from finnCap can be obtained by registering on the link above 27 September 2021 – Destiny Pharma – China progress – CMS establishes new dermal programme
	Equity Development 08 November 2021 – Support on both fronts 27 September 2021 – New dermal collaboration on XF-73
	Proactive Investors For further commentary and interviews, please visit the Destiny Pharma page at Proactive Investors on the link above